1. Ingraham NE, Barakat AG, Reilkoff R, Bezdicek T, Schacker T, Chipman JG, Tignanelli CJ, Puskarich MA: Understanding the renin–angiotensin–aldosterone–SARS-CoV axis: a comprehensive review. Eur Respir J 2020, 56(1).
2. Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, Rodriguez-Mori JE, Renna N, Chang TI, Corrales-Medina V: Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. The Lancet Respiratory Medicine 2021.
3. Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J: Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 2012, 345.
4. Lai CC, Wang YH, Wang CY, Wang HC, Yu CJ, Chen L: Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis 2018, 13:867-874.
5. Davis TM, Davis WA: Influence of Renin-Angiotensin System Inhibitors on Lower–Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care 2020, 43(9):2113-2120.
6. Christiansen CF, Heide‐Jørgensen U, Rasmussen TB, Bodilsen J, Søgaard OS, Maeng M, Vistisen ST, Schmidt M, Pottegård A, Lund LC: Renin–Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study. Journal of the American Heart Association 2020, 9(19):e017297.
7. Wu H, Lau ES, Ma RC, Kong AP, Wild SH, Goggins W, Chow E, So W-Y, Chan JC, Luk AO: Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001–2016: a retrospective cohort study. Diabetologia 2020, 63(4):757-766.
8. Luk AOY, Lau ESH, Cheung KKT, Kong APS, Ma RCW, Ozaki R, Chow FCC, So WY, Chan JCN: Glycaemia control and the risk of hospitalisation for infection in patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetes Metab Res Rev 2017, 33(8).
9. Schrijvers BF, De Vriese AS, Flyvbjerg A: From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocrine Reviews 2004, 25(6):971-1010.
10. Fu EL, Clase CM, Evans M, Lindholm B, Rotmans JI, Dekker FW, van Diepen M, Carrero JJ: Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study. Am J Kidney Dis 2021, 77(5):719-729 e711.
11. Chou C-Y, Wang S-M, Liang C-C, Chang C-T, Liu J-H, Wang I-K, Hsiao L-C, Muo C-H, Huang C-C, Wang R-Y: Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings: a nationwide population-based study. Medicine 2014, 93(27).
12. Chan JC, Lim L-L, Luk AO, Ozaki R, Kong AP, Ma RC, So W-Y, Lo S-V: From Hong Kong Diabetes Register to JADE Program to RAMP-DM for data-driven actions. Diabetes Care 2019, 42(11):2022-2031.
13. Yang A, Wu H, Lau ESH, Ma RCW, Kong APS, So WY, Luk AOY, Chan JCN, Chow E: Trends in Glucose-Lowering Drug Use, Glycemic Control, and Severe Hypoglycemia in Adults With Diabetes in Hong Kong 2002-2016. Diabetes Care 2020.
14. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A: COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006, 28(2):346-351.
15. Gokhale M, Stürmer T, Buse JB: Real-world evidence: the devil is in the detail. Diabetologia 2020, 63(9):1694-1705.
16. Thomas LE, Li F, Pencina MJ: Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial. JAMA 2020, 10.1001/jama.2020.7819.
17. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ et al: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(25 Suppl 2):S49-73.
18. Zhou Z, Rahme E, Abrahamowicz M, Pilote L: Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 2005, 162(10):1016-1023.
19. Martinussen T, Scheike TH: Dynamic regression models for survival data: Springer Science & Business Media; 2007.
20. Scheike T, Martinussen T, Silver J, Holst K: timereg: Flexible Regression Models for Survival Data. R package version 2021, 1(9).
21. Murad H, Dankner R, Berlin A, Olmer L, Freedman LS: Imputing missing time-dependent covariate values for the discrete time Cox model. Statistical Methods in Medical Research 2020, 29(8):2074-2086.
22. Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H: Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 2016, 67(5):728-741.
23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604-612.
24. Kim H-S, Lee S, Kim JH: Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. Journal of Korean Medical Science 2018, 33(34).
25. de Abajo FJ, Rodríguez-Miguel A, Rodríguez-Martín S, Lerma V, García-Lledó A: Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study. BMC Medicine 2021, 19(1):1-15.
26. Chung MK, Karnik S, Saef J, Bergmann C, Barnard J, Lederman MM, Tilton J, Cheng F, Harding CV, Young JB: SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine 2020, 58:102907.
27. Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD: Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. New England Journal of Medicine 2020, 382(17):1653-1659.
28. Chan JC, Wat NM, So W-Y, Lam KS, Chua C-T, Wong K-S, Morad Z, Dickson TZ, Hille D, Zhang Z: Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study. Diabetes Care 2004, 27(4):874-879.
29. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF: Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? Journal of the American College of Cardiology 2018, 71(13):1474-1482.
30. van de Garde EM, Souverein PC, Hak E, Deneer VH, van den Bosch JM, Leufkens HG: Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. Journal of hypertension 2007, 25(1):235-239.
31. Chung S-C, Providencia R, Sofat R: Association between angiotensin blockade and incidence of influenza in the United Kingdom. New England Journal of Medicine 2020, 383(4):397-400.
32. Pazzagli L, Linder M, Zhang M, Vago E, Stang P, Myers D, Andersen M, Bahmanyar S: Methods for time-varying exposure related problems in pharmacoepidemiology: An overview. Pharmacoepidemiology and drug safety 2018, 27(2):148-160.
33. Soto M, Bang SI, McCombs J, Rodgers KE: Renin Angiotensin system-modifying therapies are associated with improved pulmonary health. Clinical Diabetes and Endocrinology 2017, 3(1):1-9.
34. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang C-CH, Newman A, Loehr L, Folsom AR, Elkind MS: Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015, 313(3):264-274.
35. Woo KS, Nicholls M: High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995, 40(2):141.